AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/03/21

Aurinia Pharma (NASDAQ:AUPH): Q3 GAAP EPS of -$0.39 misses by $0.06. Revenue of $14.66M beats by $0.51M. Shares +1.56% PM. Press Release Gross margin for the three and nine months ended September 30, 2021 was approximately 98% and 97% respectively. “We are very pleased with Q3 res...

$14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021) Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to gro...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $14.15M. Aurinia shares rose 14% in reaction to posting financial results for Q2 ended June...

AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...

- Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021 – - Updated interim analysis shows sustained safety and tolerability of LUPKYNIS compare...

Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 1.3% after GlaxoSmithKline (NYSE:GSK) denied a Mail report from Sunday that the company was considering a bid for the company. A GSK spokeswoman told Reuters the report isn't true. Aurinia (AUPH) gained last week after speculation that seve...

Aurinia Pharmaceuticals (NASDAQ:AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers, according to Cantor Fitgzerald. Aurinia rose 1.5%. Other companies that could be interested include Amgen (NASDAQ:AMGN), AbbVie (NYSE:ABBV), J...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded today at a new 52-week high of $32.65. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 4.4 million shares. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides produc...

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 4.4% after speculation that several other pharma companies may be looking at the company. GlaxoSmithKline (NYSE:GSK), Roche (OTCQX:RHHBY) and Otsuka Pharmaceuticals (OTCPK:OTSKF)  are speculated are speculated to reviewing a poten...

Oppenheimer has downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from outperform to perform following a report that the company may be acquired by Bristol-Myers Squibb (NYSE:BMY). In addition, the firm says that the current share price reflects appropriate valuation. Oppenheimer has a $32 pri...